Low-density lipoprotein receptor-related protein-1 (LRP1) targeting contrast-enhanced MRI as a novel strategy for epilepsy imaging

• Type of Material: Article
• Authors: Dongshuang Lu, Harvard University; Phillip Zhe Sun, Emory University
• Language: English
• Date: 2021-01-22
• Publisher: Elsevier
• Publication Version: Final Published Version
• Copyright Statement: © 2021 The Authors. Published by Elsevier B.V.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.ebiom.2021.103212
• Title of Journal or Parent Work: eBioMedicine
• Volume: 64
• Start Page: 103212
• End Page: 103212
• Grant/Funding Information: None declared
• Keywords: Science & Technology; Life Sciences & Biomedicine; General & Internal Medicine; Research & Experimental Medicine; Medicine, Research & Experimental; Medicine, General & Internal

Abstract

In this article of EBioMedicine [1], Li and colleagues developed a micellar-based lipoprotein receptor-related protein-1 (LRP1)- targeting T1 MRI contrast agent as a novel approach to map the epileptic foci. Their work showed that although the blood brain barrier (BBB) in the epileptic region of drug-resistant epileptic (DRE) patients and kainate mouse models were mostly intact, there was a notable increase in the expression of LRP1. This observation provides a novel strategy for using the LRP1-targeting agent to map the lesion, independent of BBB leakage in kainate mouse models.